Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity was posted on October 2, 2008. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Adjuvant Development Program

Awarded
BAA-NIH-NIAID-DAIT-08-11Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The Adjuvant Development Program, identified by solicitation number BAA-NIH-NIAID-DAIT-08-11, seeks to advance a novel class of vaccine adjuvants that stimulate the innate immune response toward licensure for human use. The program focuses on developing these adjuvants for use with licensed or new investigational vaccine immunogens to protect against NIAID Category A, B, or C Priority Pathogens. Supported activities include lead compound optimization, immunological characterization studies, and Investigational New Drug enabling studies over a period not exceeding five years. While the primary requirement is to conduct studies on at least one Category A, B, or C Priority Pathogen, additional research on other human infectious pathogens may be permitted if there is a clear application to Biodefense. However, studies involving HIV are explicitly excluded from support. This initiative is managed by the NIAID and is categorized under NAICS code 541711.

General Info

Agency

N/A

Contract Value

$16,861,540

NAICS

541711 - Research and Development in Biotechnology

Place of Performance

AUS

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded
Posted

Presolicitation

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts2 people available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Bernard TurnerContract Specialist
Thomas P Hastings-TickerhoffContracting Officer

Full Description

Show more
The purpose of this solicitation is to establish a new Adjuvant Development Program to advance a novel class of vaccine adjuvants towards licensure for human use. This novel class of adjuvants stimulates the innate immune response and demonstrates strong adjuvant properties in animal models. These candidate vaccine adjuvants will be developed for human use with currently licensed or new investigational vaccine immunogens, to protect against NIAID Category A, B, or C Priority Pathogens. This initiative supports the development of candidate vaccine adjuvants through immunological characterization studies, lead compound optimization, and/or Investigational New Drug (IND)-enabling studies, for a period not to exceed five (5) years. Work must include studies on at least one Category A, B, or C Priority Pathogen. Additional studies may be focused on other human infectious pathogens with sufficient justification of an ultimate application to Biodefense. Studies with HIV will not be supported.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS